Xsolla Brings Mobile-First Monetization Expertise to Gamesforum Barcelona 2026, Where Europe's Mobile Gaming Leaders Gather to Solve the Industry's Toughest Growth Challenges
9.2.2026 20:30:00 CET | Business Wire | Press Release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its participation in Gamesforum Barcelona 2026, taking place Feb.10-11 at the InterContinental Hotel in Barcelona. This event brings together Europe's sharpest minds in mobile gaming for practical, data-driven sessions focused on what actually works in today's hypercompetitive mobile landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209301026/en/
(Graphic: Xsolla)
With over 600 professionals from Europe's top publishers, ad networks, and studios in attendance, Gamesforum Barcelona has earned its reputation as the place where mobile gaming's most pressing problems get solved: How do you scale profitably? How do you retain players in saturated markets? How do you monetize without alienating your audience?
"Gamesforum Barcelona represents everything we value about the European mobile gaming community, it's pragmatic, data-obsessed, and laser-focused on sustainable growth," said Berkley Egenes, Chief Marketing & Growth Officer at Xsolla. "The mobile developers we meet at Gamesforum aren't looking for hype. They're looking for solutions that move the needle on LTV, reduce churn, and give them leverage against platform economics that weren't designed for their success. We've spent years solving these exact problems for hundreds of mobile studios, and we're excited to share what's actually working in 2026."
Xsolla is at the forefront of these important conversations:
- 700+ Web Shops Launched for Mobile Games: Xsolla doesn't just talk about direct-to-consumer—we've built it at scale. Over 700 mobile game studios have implemented Xsolla's "Pay Online, Play on Device" web shop model, bypassing platform fees, keeping more revenue, and building direct player relationships. This isn't experimental. It's currently in use by studios across Europe, Asia, and the Americas.
- Global Payments That Actually Convert: Supporting 1,000+ payment methods across 200+ geographies sounds impressive until you realize what it means in practice: players in Poland can pay with Blik, players in Brazil use Pix, players in Southeast Asia use local e-wallets—and your conversion rates stop bleeding. Mobile developers live and die by conversion optimization, and local payment support is where the biggest gains happen.
- Infrastructure Built for Mobile's Reality: Mobile game studios don't have time to build payment systems, combat fraud, manage compliance across dozens of markets, or navigate platform policies. Xsolla handles the complex, unglamorous backend so developers can focus on what they're actually good at: making games players love and can't stop playing.
The European mobile gaming market is one of the most sophisticated and competitive in the world. Studios here operate on thin margins, with high player expectations and constant pressure to optimize every step of the funnel. Gamesforum Barcelona reflects this reality: it's where monetization teams come to learn from one another, where UA professionals share what drives results, and where product leaders figure out how to build sustainable businesses in an increasingly challenging market.
Xsolla's participation goes beyond a booth presence. The company's team will be on the ground for hands-on conversations about the real challenges mobile studios face: web shop economics, regional payment optimization, platform diversification strategies, and building scalable D2C capabilities. These aren't sales pitches, they're strategy sessions with teams who've been in the trenches.
Mobile game developers, publishers, UA teams, and monetization professionals attending Gamesforum Barcelona 2026 are invited to connect with Xsolla's business development and product specialists to discuss specific challenges, share data on what's working in their markets, and explore how Xsolla's infrastructure can support their growth objectives.
To schedule a meeting with Xsolla during Gamesforum Barcelona, visit: xsolla.pro/gamesforum-barcelona
About Xsolla
Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.
For more information, visit xsolla.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260209301026/en/
Contacts
Media Contact
Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom